Will the new psoriasis drug in 2025 be deuterated coxitinib/sondido?

Plaque psoriasisis a chronic inflammatory disease with a huge demand for treatment. Every year, patients pay attention whether there are newer drugs. In the psoriasis drug landscape in 2025, Deucravacitinib is undoubtedly a high-profile choice. Judging from the international launch time, the U.S. FDA approved the drug as early as September 2022, the European Union followed closely in March 2023, and the China State Food and Drug Administration also approved Sondido in October 2023, which shows its wide recognition around the world. As the first oral TYK2 inhibitor to be marketed, it represents an innovation in the treatment paradigm of psoriasis.

Traditional treatments include topical drugs, phototherapy, systemic drugs and biological agents. Although biological agents have made breakthroughs in the past decade, they still have limitations such as high price, the need for injection, and inconvenience for long-term use. Deuterated colexitinib is an oral small molecule drug that combines precise targeting and ease of use, which meets the core demands of many psoriasis patients.

Judging from international cutting-edge research, the drug has shown good lasting efficacy and safety in the treatment of moderate to severe psoriasis, making doctors more willing to recommend it as a long-term treatment option. Compared with traditional immunosuppressants, it does not require frequent monitoring of severe organ toxicity and reduces patients' dependence on injection therapy. Although more targeted drugs may be approved in the next few years, deuterated colexitinib is very likely to become a "new drug" that psoriasis patients will pay attention to in 2025 due to its "oral, effective and safe" characteristics.

Therefore, it can be said that inthe new pattern of psoriasis treatment in 2025, deuterated coxitinib is not only a new drug, but also a turning point in the treatment model. Its launch gives patients a more balanced choice in addition to biological agents and traditional drugs. This is undoubtedly a new hope for patients who have long coexisting with psoriasis.

Reference materials:https://go.drugbank.com/drugs/DB16650